Navigation Links
OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial
Date:3/14/2012

excellence with key opinion leaders in melanoma clinical research for its metastatic melanoma phase II study.

About OncoSec's Metastatic Melanoma Phase II Study (OMS-I100)

A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

OMS ElectroImmunotherapy utilizes OncoSec's proprietary technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using OMS ElectroImmunotherapy to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.

About Melanoma

Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable, but if it is not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths. The American Cancer Society estimates that at present, about 123,000 new cases of melanoma in the US are diagnos
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy
2. OncoSecs OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper
3. OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma
4. OncoSec to Present at World Cancer Immunotherapy Conference
5. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
6. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
7. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
8. OncoSec to Present at Medical Device Investor Forum
9. Device Master File for OncoSec Medical System Completed and Submitted to FDA
10. OncoSec Releases Devices for Use in Clinical Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as ... New York City on Wednesday April 22.  ... ... ... Thirty percent (30%) of all cardiovascular disease is caused ...
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... April 21, 2015  Navitas has launched Aviator, a ... range of offerings for life sciences clients. Aviator supports ... platform enabling seamless flow of data across all applications ... launch, Navitas worked closely with Oracle to provide Argus, ... CTMS in the Cloud. ...
Breaking Medicine Technology:IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
... June 21 Gentris Corporation ( www.gentris.com ), ... that Rick Williams has joined the organization ... Board of Directors.  In his role as CEO of ... continues to provide biotechnology and pharmaceutical sponsors with the ...
... 21 Thomson Reuters announced today that it has launched ... the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around ... , ... with drugs in development. It enables authorized users to share essential ...
Cached Medicine Technology:Gentris Corporation Names New Chief Executive Officer 2Gentris Corporation Names New Chief Executive Officer 3Gentris Corporation Names New Chief Executive Officer 4Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3
(Date:4/21/2015)... Chicago, IL (PRWEB) April 21, 2015 ... surgery provider in India for their ongoing commitment to ... Hyderabad strives to provide patients with the best ... to the skin, hair and body. , Executives at ... believes in the philosophy of — nothing about you, ...
(Date:4/21/2015)... Lewisville, TX (PRWEB) April 21, 2015 ... (NYSE:ADPT) announced today it is opening its first freestanding ... located in Chandler, Arizona and will be licensed under ... of the Dignity Health and Adeptus Health joint venture. ... Chandler Regional and Mercy Gilbert Medical Centers said the ...
(Date:4/21/2015)... Information is the best weapon in the fight ... patients and their families with knowledge about living with cancer ... is the Answer" and new website . , In ... patients from diagnosis through treatment and even death. The goal, ... treatment, at home and in the examination room. , “Cancer ...
(Date:4/21/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining ... SUVs. , SUVs are large vehicles that fare well ... and a smaller regular car shows that passengers from the ... SUV safer in crashes, but these large vehicles may be ... , It is now possible to find low cost car ...
(Date:4/21/2015)... QuickMedical, a veteran-owned leader in the ... Schiller America's line of Ambulatory and ... Vital Signs Monitors, among many other items. ... leader in the development and production of cardio-pulmonary ... cooperation with the world's leading physicians and specialists ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3
... world-leading publisher of scientific, technical, and medical information products ... January 2009, the internationally respected Journal of Pain ... be the official journal of the American Academy of ... will continue to serve as the official journal ...
... in Laser and Endoscopic Surgery , , ... Schaeffer, endoscopic reconstructive surgeon and leading nasal expert, has retained ... cosmetic practice. , , ... face, neck, sinuses and skull base, Dr. Schaeffer is credited ...
... 17 Cadence Pharmaceuticals, Inc.,(Nasdaq: CADX ... 304, a,Phase III clinical trial of Acetavance(TM), the ... acute pain following,abdominal laparoscopic surgery. Study 304 ... reduction in summed pain intensity,differences from baseline over ...
... NEW YORK, Dec. 17 Forest Laboratories, Inc. (NYSE: ... Chief Executive Officer exercised stock options for 600,000 shares which ... their 10-year term. Mr. Solomon indicated his intent to ... option exercise, net of those shares withheld by the Company ...
... is linked to hepatitis B, researchers say , , ... increased overall survival in Asian-Pacific patients with advanced liver ... included 226 patients in China, South Korea and Taiwan. ... 400 milligrams of sorafenib (Nexavar) twice a day in ...
... Internet,s fastest-growing job site, predicts the job sectors most likely to ... ... McLean, VA (PRWEB) December 17, 2008 -- Jobfox, the ... trends to watch in 2009. The list includes the job ...
Cached Medicine News:Health News:Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM 2Health News:Rubenstein Public Relations Retained To Provide Publicity for Foremost Nasal and Cosmetic Surgeon 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 3Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 4Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 5Health News:Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares 2Health News:Drug Helps Asians Battling Liver Cancer 2Health News:The Obama Effect: New Job Trends to Watch in 2009 2Health News:The Obama Effect: New Job Trends to Watch in 2009 3
... The Fundus 20mm is a ... Lens. The Fundus 20mm provides ... increased 20mm contact element. The ... the contact element sits under ...
... The Volk Area Centralis® is excellent ... neovascularization and changes from macular degeneration, ... proliferative diabetic retinopathy and other retinal ... laser treatment of these conditions providing ...
... delivers the widest field of view ... .5x image magnification provides simultaneous visualization of ... providing a greater margin of safety during ... the ideal lens for visualization and treatment ...
... it the "Super 90". Volk's SuperField® has ... diagnosis for today's discriminating practitioner. Its ideal ... make it perfect as the primary high ... SuperField has been specifically designed for increased ...
Medicine Products: